145 related articles for article (PubMed ID: 8572666)
1. Intravenous antigen administration as a therapy for autoimmune demyelinating disease.
Racke MK; Critchfield JM; Quigley L; Cannella B; Raine CS; McFarland HF; Lenardo MJ
Ann Neurol; 1996 Jan; 39(1):46-56. PubMed ID: 8572666
[TBL] [Abstract][Full Text] [Related]
2. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein.
Elliott EA; McFarland HI; Nye SH; Cofiell R; Wilson TM; Wilkins JA; Squinto SP; Matis LA; Mueller JP
J Clin Invest; 1996 Oct; 98(7):1602-12. PubMed ID: 8833909
[TBL] [Abstract][Full Text] [Related]
3. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin antigens: IV. Suppression of chronic relapsing disease in the Lewis rat and strain 13 guinea pig.
Brod SA; al-Sabbagh A; Sobel RA; Hafler DA; Weiner HL
Ann Neurol; 1991 Jun; 29(6):615-22. PubMed ID: 1716432
[TBL] [Abstract][Full Text] [Related]
4. Experimental autoimmune encephalomyelitis: the antigen specificity of T lymphocytes determines the topography of lesions in the central and peripheral nervous system.
Berger T; Weerth S; Kojima K; Linington C; Wekerle H; Lassmann H
Lab Invest; 1997 Mar; 76(3):355-64. PubMed ID: 9121118
[TBL] [Abstract][Full Text] [Related]
5. Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis.
Weishaupt A; Kuhlmann T; Schönrock LM; Toyka KV; Brück W; Gold R
Acta Neuropathol; 2002 Oct; 104(4):385-90. PubMed ID: 12200625
[TBL] [Abstract][Full Text] [Related]
6. In vivo immunomodulation by monoclonal anti-CD4 antibody. II. Effect on T cell response to myelin basic protein and experimental allergic encephalomyelitis.
Sriram S; Carroll L; Fortin S; Cooper S; Ranges G
J Immunol; 1988 Jul; 141(2):464-8. PubMed ID: 2454992
[TBL] [Abstract][Full Text] [Related]
7. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1.
Racke MK; Dhib-Jalbut S; Cannella B; Albert PS; Raine CS; McFarlin DE
J Immunol; 1991 May; 146(9):3012-7. PubMed ID: 1707929
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of suppression of experimental autoimmune encephalomyelitis by intravenous administration of myelin basic protein: role of regulatory spleen cells.
Hilliard BA; Kamoun M; Ventura E; Rostami A
Exp Mol Pathol; 2000 Feb; 68(1):29-37. PubMed ID: 10640452
[TBL] [Abstract][Full Text] [Related]
9. Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice.
Tran EH; Hoekstra K; van Rooijen N; Dijkstra CD; Owens T
J Immunol; 1998 Oct; 161(7):3767-75. PubMed ID: 9759903
[TBL] [Abstract][Full Text] [Related]
10. Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: a new model for multiple sclerosis.
Massacesi L; Genain CP; Lee-Parritz D; Letvin NL; Canfield D; Hauser SL
Ann Neurol; 1995 Apr; 37(4):519-30. PubMed ID: 7717689
[TBL] [Abstract][Full Text] [Related]
11. Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
Garay L; Gonzalez Deniselle MC; Gierman L; Meyer M; Lima A; Roig P; De Nicola AF
Neuroimmunomodulation; 2008; 15(1):76-83. PubMed ID: 18667803
[TBL] [Abstract][Full Text] [Related]
12. Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler's virus-induced demyelinating disease.
Fuller KG; Olson JK; Howard LM; Croxford JL; Miller SD
Methods Mol Med; 2004; 102():339-61. PubMed ID: 15286394
[TBL] [Abstract][Full Text] [Related]
13. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion.
Korn T; Magnus T; Toyka K; Jung S
J Leukoc Biol; 2004 Nov; 76(5):950-60. PubMed ID: 15328336
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitis.
Benson JM; Stuckman SS; Cox KL; Wardrop RM; Gienapp IE; Cross AH; Trotter JL; Whitacre CC
J Immunol; 1999 May; 162(10):6247-54. PubMed ID: 10229871
[TBL] [Abstract][Full Text] [Related]
15. Propentofylline and iloprost suppress the production of TNF-alpha by macrophages but fail to ameliorate experimental autoimmune encephalomyelitis in Lewis rats.
Jung S; Donhauser T; Toyka KV; Hartung HP
J Autoimmun; 1997 Dec; 10(6):519-29. PubMed ID: 9451591
[TBL] [Abstract][Full Text] [Related]
16. Chronic relapsing necrotizing encephalomyelitis produced by myelin basic protein in mice.
Moore GR; McCarron RM; McFarlin DE; Raine CS
Lab Invest; 1987 Aug; 57(2):157-67. PubMed ID: 2441138
[TBL] [Abstract][Full Text] [Related]
17. Evidence that Fas and FasL contribute to the pathogenesis of experimental autoimmune encephalomyelitis.
Dittel BN
Arch Immunol Ther Exp (Warsz); 2000; 48(5):381-8. PubMed ID: 11140465
[TBL] [Abstract][Full Text] [Related]
18. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system.
Yan SS; Wu ZY; Zhang HP; Furtado G; Chen X; Yan SF; Schmidt AM; Brown C; Stern A; LaFaille J; Chess L; Stern DM; Jiang H
Nat Med; 2003 Mar; 9(3):287-93. PubMed ID: 12598893
[TBL] [Abstract][Full Text] [Related]
19. Epicutaneous (EC) immunization with myelin basic protein (MBP) induces TCRalphabeta+ CD4+ CD8+ double positive suppressor cells that protect from experimental autoimmune encephalomyelitis (EAE).
Tutaj M; Szczepanik M
J Autoimmun; 2007 Jun; 28(4):208-15. PubMed ID: 17442539
[TBL] [Abstract][Full Text] [Related]
20. Local delivery of cytokines by retrovirally transduced antigen-specific TCR+ hybridoma cells in experimental autoimmune encephalomyelitis.
Dal Canto RA; Costa G; Shaw MD; Seroogy C; Nolan GP; Fathman CG
Eur Cytokine Netw; 1998 Sep; 9(3 Suppl):83-91. PubMed ID: 9831193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
